SightMD New Jersey proudly announces that Dr. Anil Birdi has successfully performed the practice's first Implantable Collamer Lens (ICL) surgery. This groundbreaking procedure, completed at the end of 2024, marks a significant advancement for SightMD New Jersey as they continue expanding their offerings in advanced vision correction.
HAUPPAUGE, N.Y., Feb. 13, 2025 /PRNewswire-PRWeb/ -- SightMD New Jersey proudly announces that Dr. Anil Birdi has successfully performed the practice's first Implantable Collamer Lens (ICL) surgery. This groundbreaking procedure, completed at the end of 2024, marks a significant advancement for SightMD New Jersey as they continue expanding their offerings in advanced vision correction.
ICL, or Implantable Collamer Lens, is a refractive lens that is surgically implanted in the eye to correct vision issues such as myopia (nearsightedness) and astigmatism. Unlike LASIK, ICL does not involve reshaping the cornea. Instead, the lens is placed between the iris and the natural lens, providing a reversible and additive approach to vision correction. ICL is known for its ability to deliver high-definition vision and is an excellent option for patients who may not be suitable candidates for other laser-based procedures or are looking for a vision correction procedure without removal of tissue.
Dr. Anil Birdi, a leading ophthalmologist at SightMD New Jersey, expressed his enthusiasm for this achievement, stating, "I am thrilled to bring EVO ICL surgery to our patients in New Jersey. This procedure opens up new possibilities for those seeking a long-term solution to nearsightedness and astigmatism, and I am excited to continue providing innovative options for vision correction."
EVO ICL surgery is a cutting-edge alternative for patients who may not be candidates for LASIK or PRK. The lens is implanted between the iris and the natural lens, providing enhanced vision without removing any corneal tissue.The quality of vision that can be achieved is excellent.
Dr. Alexander Hatsis, a renowned EVO ICL surgeon at SightMD New York, congratulated Dr. Birdi and highlighted the importance of this milestone, saying, "I am incredibly proud of Dr. Birdi and the entire SightMD New Jersey team for expanding access to EVO ICL surgery. This achievement reflects our shared commitment to delivering state-of-the-art vision correction procedures across the region."
Patients interested in learning more about EVO ICL surgery are encouraged to visit SightMD's website or one of the following locations: Toms River, NJ; Brick, NJ; Barnegat, NJ; Rockville Centre, NY; Elkins Park, PA; and Manchester, CT.
About SightMD New Jersey
SightMD New Jersey offers patients access to 16 eye care doctors through the convenience of 8 clinical locations and 1 Ambulatory Surgery Center in New Jersey. Its services include LASIK and refractive eye surgery, cataract surgery, macular degeneration, pediatric eye care, diabetic eye disease, glaucoma care, dry eye management, and general eye exams. Sight Growth Partners is the administrative services provider for SightMD New Jersey, as well as SightMD Pennsylvania, SightMD Connecticut and SightMD in New York. For more information about SightMD New Jersey, please visit sightmd.com
Media Contact
Stephanie Penza, SightGrowthPartners, 6318352613, [email protected], www.sightmd.com
SOURCE SightMD New Jersey
Share this article